17.12
+3.19%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AVITA Medical
From its filings with the US Securities and Exchange Commission
AVITA Medical is based in Valencia, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RCEL. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $71.6m and a net loss of $48.6m. At that date it held total assets of $56.4m and shareholders' equity of −$16.6m. By region, UNITED STATES accounted for 96.1%, followed by JAPAN at 2.9% and UNITED KINGDOM at 0.7%.
AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Our technologies address critical healing needs arising from burns, traumatic injuries and surgical repairs, through a portfolio of proprietary and complementary products that support wound bed preparation, definitive closure, and recovery.
Our current commercial portfolio includes RECELL® (“RECELL”), and two complementary wound care products, PermeaDerm® and Cohealyx, which together support a comprehensive standard of care for acute wounds.
At the forefront of our portfolio is RECELL, approved by the United States Food & Drug Administration (the “FDA”) for the treatment of thermal burn wounds and full-thickness skin defects. While RECELL is also approved in the United States for restoring pigmentation of stable depigmented vitiligo lesions, we have paused further commercial investment in vitiligo at this time.
In 2024 and 2025, we expanded our product offerings to address additional acute wound care needs. In January 2024, we entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. (“Stedical”) to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix in the United States (“U.S.”). In March 2025, we entered into a multi-year agreement to also manufacture PermeaDerm.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Mar 2012
- Employees
- 226
- Website
- avitamedical.com ↗
- Head office
- 28159 AVENUE STANFORD, VALENCIA, CA, 91355
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Lou PanaccioIndependent Non-Executive Chairman of the board, since 2014$235,252
- Mr. James CorbettPresident, Chief Executive Officer, Executive Director, since 2021$3.2m
- Mr. David O'TooleChief Financial Officer$1.8m
- Ms. Nicole KelseyChief Legal and Compliance Officer, Corporate Secretary$1.3m
- Dr. Michael TarnoffIndependent Director
- Mr. Jeremy CookIndependent Non-Executive Director$196,029
- Prof. Suzanne CroweIndependent Non-Executive Director$196,029
- Mr. Robert McnamaraIndependent Non-Executive Director$203,141
- Ms. Jan ReedIndependent Non-Executive Director$209,474
- Mr. Cary VanceIndependent Non-Executive Director$207,752
- Ms. Jessica EkebergDirector - Investor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 45
- Environment
- 46
- Social
- 65
- Governance
- 23
- Women in the workforce
- 50.2%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Advanced Technology: AVITA Medical Inc utilizes cutting-edge medical technology in their products and services, providing them with a competitive advantage in the market.
- Strong Research and Development: The company invests heavily in R&D, allowing them to continuously innovate and develop new, effective solutions for the medical industry.
- Established Market Presence: AVITA Medical Inc has built a solid reputation and established relationships with key stakeholders, including healthcare professionals and institutions.
- Strong Financial Position: The company boasts a healthy financial standing, enabling them to fund their operations and pursue growth opportunities.
Weaknesses
- Limited Product Portfolio: AVITA Medical Inc currently offers a limited range of products, which may limit their market reach and revenue potential.
- Dependence on Regulatory Approvals: The company's success heavily relies on obtaining necessary approvals from regulatory authorities, which can delay product launches and impact profitability.
- Relatively Small Customer Base: AVITA Medical Inc primarily caters to a niche market, which may result in limited customer base and slower market expansion.
Opportunities
- Growing Demand for Regenerative Medicine: The increasing focus on regenerative medicine presents an opportunity for AVITA Medical Inc to expand their product offerings and capture a larger market share.
- Expansion into New Geographical Markets: The company can explore untapped international markets to diversify their customer base and drive revenue growth.
- Strategic Partnerships and Collaborations: AVITA Medical Inc can leverage strategic partnerships and collaborations with other industry players to enhance their technological capabilities and market presence.
Threats
- Intense Competition: The medical industry is highly competitive, and AVITA Medical Inc faces competition from established players as well as emerging startups.
- Evolving Regulatory Landscape: Changes in regulations and compliance requirements can impact AVITA Medical Inc's operations and product development processes.
- Technological Advancements: Rapid technological advancements may render AVITA Medical Inc's existing products obsolete or less relevant, requiring continuous innovation to stay competitive.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.